NI Research has released the November/December issue of NeuroPerspective, which features comprehensive reviews of two major therapeutic areas, Multiple Sclerosis and Pain (non-neuropathic). As NeuroPerspective publisher Harry Tracy PhD notes: “the areas of MS and Pain share some attributes: While the industry has enjoyed great commercial success, and there are treatments in each area that offer therapeutic benefit, there is a price to be paid for these successes. In MS, there is a perennial tradeoff between the magnitude of impact and the risk of a compromised immune system less able to fend off infections and/or cancer, while the treatment of pain has fostered an epidemic of prescription opioid and heroin addiction. There is a high need for improvement in the options available for both therapeutic areas.”
Multiple Sclerosis represents the area where neuroscience has achieved the greatest progress towards slowing the course of a CNS disease, and where patients and their physicians can choose from a variety of treatment approaches (i.e. the ABC drugs, Tysabri, the oral immunomodulators) for the treatment of RRMS. Yet all of these drugs have their own flaws and risks, and there have been no real options for Progressive MS. Both Roche and Novartis have now reported positive Phase III results in Progressive MS, for ocrelizumab and sipinimod respectively. MS is also the area where regenerative therapies are likely to emerge as an avenue to repairing the damage done, and while the first trial of Biogen’s anti-lingo program failed, there are glimmers of hope from the retrospective dosing analysis that this may yet be fruitful. This review covers programs from Biogen, Roche, Novartis, Teva, Sanofi, Acorda, MedDay, Merck Serono, Actelion, and many more.
Pain (nociceptive/inflammatory; neuropathic pain is reviewed separately by NIR) is a ubiquitous affliction for humankind, one where some of the most effective current treatment options, the opioids, are also among the riskiest of therapeutic agents, imbued as they are with the danger of addiction, which has translated into a well-publicized epidemic. Besides the continuing search for analgesic alternatives that might approach opioid efficacy, there has been a parallel effort to develop opioids that are formulated to reduce the risk of abuse and dependency. The Pain review covers programs from Teva Pharma, Purdue Pharma, Egalet, Cara Therapeutics, Depomed, Trevena, Epiodyne, Quartet Medicine, Centrexion, Wex Pharma, and many others.
This 64 page issue also includes:
1) A discussion of the Phase III results for ITI-007 from Intra-Cellular Therapies and for ALKS 5461 from Alkermes. What can be expected from the FDA in the wake of recent moves towards flexibility?
2 ) The Pharma industry continually damages itself with tone-deaf public relations. ‘Fixing the Ruptured Social Contract’ notes attempts from the CEOs of Allergan and Ovid Therapeutics to alter the industry dynamic.
3) Clinical successes from Amgen/Novartis, Teva, Alkermes, CoLucid, Sunovion, Bionomics; disappointments from TauRx, Intra-Cellular, Otsuka/Lundbeck.
4) The Company Spotlight reviews covers Centrexion Therapeutics; there is also an excerpted (from NeuroLicensing 2016-17) assessment of Johnson & Johnson/Janssen.
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.
A one-year (1-5 user) subscription to NeuroPerspective is $2525. Special startup and academic pricing is available. The MS/Pain review issue of NeuroPerspective is being made available as a single-issue purchase for $500.Read More